ReShape Lifesciences Inc (NASDAQ:RSLS) price on Wednesday, April 30, fall -1.74% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $0.34.
A look at the stock’s price movement, the close in the last trading session was $0.34, moving within a range at $0.325 and $0.3436. The beta value (5-Year monthly) was 1.925. Turning to its 52-week performance, $29.00 and $0.30 were the 52-week high and 52-week low respectively. Overall, RSLS moved -6.10% over the past month.
ReShape Lifesciences Inc’s market cap currently stands at around $3.81 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Apr-03.
Turning to the stock’s technical picture we see that short term indicators suggest on average that RSLS is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
1 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 1 recommend RSLS as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
RSLS’s current price about -14.07% and -49.30% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 41.13, while 7-day volatility ratio is 7.24% and 38.83% in the 30-day chart. Further, ReShape Lifesciences Inc (RSLS) has a beta value of 1.48, and an average true range (ATR) of 0.15.
If we refocus on ReShape Lifesciences Inc (NASDAQ:RSLS), historical trading data shows that trading volumes averaged 18.07 over the past 10 days and 15.70 million over the past 3 months. The company’s latest data on shares outstanding shows there are 11.28 million shares.
The 18.08% of ReShape Lifesciences Inc’s shares are in the hands of company insiders while institutional holders own 0.30% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 1.04 million on 2025-04-15, giving us a short ratio of 0.03. The data shows that as of 2025-04-15 short interest in ReShape Lifesciences Inc (RSLS) stood at 919.9999999999999 of shares outstanding, with shares short rising to 0.37 million registered in 2025-03-14. Current price change has pushed the stock -92.41% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the RSLS stock continues to rise going into the next quarter.
